Cybin Balance Sheet Health
Financial Health criteria checks 6/6
Cybin has a total shareholder equity of $273.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $290.1M and $16.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$195.13m |
| Equity | US$273.93m |
| Total liabilities | US$16.18m |
| Total assets | US$290.11m |
Recent financial health updates
Recent updates
Cybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade)
Summary I am upgrading Cybin Inc. to Buy, driven by recent regulatory and clinical tailwinds that favor its lead candidate, HLP003. HELP is positioned to benefit from expedited FDA pathways and increased institutional support, particularly for major depressive disorder and PTSD indications. The market undervalues HELP, trading near cash value with a 0.84x forward price-to-book and an $85M EV versus $195M in cash. Key HELP stock catalysts include Phase 2/3 data for HLP003, progress on HLP004, and regulatory updates, with pivotal Phase 3 top-line data expected in Q4 '26. Read the full article on Seeking Alpha
Psychedelic Therapy Trials Will Face Cash Strain Yet Could Unlock Long Term Upside
Catalysts About Cybin Cybin is a clinical stage biopharmaceutical company developing psychedelic based therapies for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?
Late Stage Psychedelic Therapies And Clinic Partnerships Will Reshape Treatment For Depression And Anxiety
Catalysts About Cybin Cybin is a clinical stage biopharmaceutical company developing psychedelic based therapies for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?
Interventional Psychiatry And Clinic Partnerships Will Support Long Term Psychedelic Treatment Adoption
Catalysts About Cybin Cybin is a clinical stage company developing psychedelic based treatments for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?Financial Position Analysis
Short Term Liabilities: HELP's short term assets ($222.9M) exceed its short term liabilities ($16.2M).
Long Term Liabilities: HELP has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: HELP is debt free.
Reducing Debt: HELP had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HELP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: HELP has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 33.1% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/07 02:55 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cybin Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| David Martin | Bloom Burton & Co. |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |